Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 4, 2004, Pages 547-550

  Harenberg, Job ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CERTOPARIN; COUMARIN DERIVATIVE; DALTEPARIN; DANAPAROID; DRUG METABOLITE; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLASMA PROTEIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; VENOUS THROMBOEMBOLISM; BLOOD; DRUG ANTAGONISM; PRACTICE GUIDELINE;

ANTICOAGULANTS; DRUG MONITORING; FACTOR XA; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRACTICE GUIDELINES;

EID: 3242734130     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7933.2004.00647.x     Document Type: Article

References (27)

1. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (Suppl. 1): 64S-94S.
2. Bratt G, Aberg W, Johannsson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64: 506-10.
3. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39: 107-12.
4. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between antifactor Xa level and clinical outcome in patients receiving enoxaparin low molecular-weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989; 62: 940-4.
5. Harenberg J, Giese Ch, Dempfle CE, Stehle G, Heene DL. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood. Thromb Haemost 1988; 60: 377-81.
6. Sie P, Aillaud MF, de Prost D, Droulle C, Forestier F, Guedj P, Juhan-Vague I, Polack B, Potron G, Roncato M. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard. Thromb Haemost 1987; 58: 879-83.
7. Barrowcliffe TW. Low molecular weight heparins. Br J Haematol 1995; 90: 1-7.
8. Harenberg J, Giese Ch, Dempfle CE, Stehle G, Heene DL. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemost 1989; 61: 357-62.
9. Collignon F, Frydman A, Caplain H. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 15: 119-23.
10. Hull R, Raskob GE, Pineo GF, Green D, Trowbridge A, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975-82.
11. Holmström MC, Berglund S, Granquist S, Bratt G, Törnebohm E, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res 1992; 67: 49-55.
12. Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. Semin Thromb Hemost 1997; 23: 83-90.
13. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-43.
14. Lindmarker P, Holstrom M, Granquist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
15. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low molecular weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 698-702.
16. Stehle G, Friedrich EA, Sinn H, Wunder A, Harenberg J, Dempfle CE, Maier-Borst W, Heene DL. Hepatic uptake of a modified low molecular weight heparin in rats. J Clin Invest 1992; 90: 2110-6.
17. Chow S, Zammit K, West K, Dannenhoffer MA, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43: 586-90.
18. Cadroy Y, Pourrat J, Baladre MF, Saivin S, Houin G, Montastruc JL, Vernier I, Boneu B. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63 385-90.
19. Harenberg J, Leber G, Dempfle CE, Heene DL, Zimmermann R, Kübler W. Long term anticoagulation with low molecular weight heparin in outpatients with side effects to oral anticoagulants. Nouv Rev Franc Hematol 1989; 31: 363-9.
20. Bremme K, van Rooijen M, Yu A, Blomback M. Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy. Blood Coagul Fibrinol 2001; 12: 149-55.
21. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, MacGillavry MR, Hamulyak K, Theunissen IM, Hunt BJ, Buller HR. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72.
22. Blomback M, Bremme K, Hellgren M, Siegbahn A, Lindberg H. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy a longitudinal safety study. Blood Coagul Fibrinol 1998; 9: 1-9.
23. Becker RC, Spencer FA, Gibson M, Rush JE, Sandering G, Murphy SA, Ball SP, Antmann EM, for the TIMI 11A Investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndrome. Am Heart J 2002; 143: 753-9.
24. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128: 313-8.
25. Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, Szechtman B, Kohne S, Shepherd S, Bacher P, Andrew M. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003; 109: 93-9.
26. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtma B, Chan AK, Andrew M. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complication in children: the PROTEKT-trial. Thromb Res 2003; 109: 101-8.
27. Laposata M, Green D, Van Cott ENM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122: 799-807.